Results 1 to 10 of about 1,837,020 (236)

Polyvalent AIDS vaccines. [PDF]

Curr HIV Res, 2010
A major hurdle in the development of a global HIV-1 vaccine is viral diversity. For close to three decades, HIV vaccine development has focused on either the induction of T cell immune responses or antibody responses, and only rarely on both components.
Lu S, Grimes Serrano JM, Wang S.
europepmc   +5 more sources

HIV/AIDS Vaccines: 2018. [PDF]

Clin Pharmacol Ther, 2018
Human immunodeficiency virus (HIV) has infected 76 million people and killed an estimated 35 million. During its 40‐year history, remarkable progress has been made on antiretroviral drugs.
Robinson HL.
europepmc   +2 more sources

HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategies. [PDF]

Pan Afr Med J, 2015
More than decades have already elapsed since human immunodeficiency virus (HIV) was identified as the causative agent of acquired immunodeficiency syndrome (AIDS). The HIV has since spread to all parts of the world with devastating effects.
Chin'ombe N, Ruhanya V.
europepmc   +2 more sources

Recombinant Salmonella Bacteria Vectoring HIV/AIDS Vaccines. [PDF]

Open Virol J, 2013
HIV/AIDS is an important public health problem globally. An affordable, easy-to-deliver and protective HIV vaccine is therefore required to curb the pandemic from spreading further.
Chin'ombe N, Ruhanya V.
europepmc   +2 more sources

Scientific and regulatory challenges in evaluating clinical trial protocols for HIV-1/AIDS vaccines – A review from a regulatory perspective

Biologicals, 2016
Clinical development of prophylactic HIV/AIDS vaccines presents many scientific challenges that result in challenges for regulators reviewing clinical trial applications (CTAs).
Rebecca Sheets, Ivana Knezevic
exaly   +2 more sources

Strategies for AIDS vaccines [PDF]

Journal of Antimicrobial Chemotherapy, 1996
In the global AIDS epidemic, over half of all infections have occurred in people less than 25 years old resulting in profound social, economic and demographic consequences. Current estimates indicate that the present 15 million HIV infections will increase to over 30 million by the end of the millennium.
E J, Stott, G C, Schild
openaire   +3 more sources

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity

Emerging Microbes and Infections, 2022
SARS-CoV-2 has caused the COVID-19 pandemic. B.1.617 variants (including Kappa and Delta) have been transmitted rapidly in India. The transmissibility, pathogenicity, and neutralization characteristics of these variants have received considerable ...
Li Zhang, Qianqian Li, Jiajing Wu, Yuanling Yu, Yue Zhang, Jianhui Nie, Ziteng Liang, Zhimin Cui, Shuo Liu, Haixin Wang, Ruxia Ding, Fei Jiang, Tao Li, Lingling Nie, Qiong Lu, Jiayi Li, Lili Qin, Yinan Jiang, Yi Shi, Wenbo Xu, Weijin Huang, Youchun Wang   +21 more
doaj   +1 more source

HIV-1 pseudoviruses constructed in China regulatory laboratory

Emerging Microbes and Infections, 2020
To better evaluate HIV-1 vaccines and therapeutics, the National Institutes for Food and Drug Control of China developed a panel of HIV-1 pseudoviruses including 462 viral strains derived from China, covering the majority of contemporaneous subtypes and ...
Jianhui Nie, Weijin Huang, Qiang Liu, Youchun Wang   +3 more
doaj   +1 more source

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

Emerging Microbes and Infections, 2020
Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to
Jianhui Nie, Qianqian Li, Jiajing Wu, Chenyan Zhao, Huan Hao, Huan Liu, Li Zhang, Lingling Nie, Haiyang Qin, Meng Wang, Qiong Lu, Xiaoyu Li, Qiyu Sun, Junkai Liu, Changfa Fan, Weijin Huang, Miao Xu, Youchun Wang   +17 more
doaj   +1 more source

The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain

Signal Transduction and Targeted Therapy, 2022
Emerging SARS-CoV-2 variants are the most serious problem for COVID-19 prophylaxis and treatment. To determine whether the SARS-CoV-2 vaccine strain should be updated following variant emergence like seasonal flu vaccine, the changed degree on ...
Jiajing Wu, Jianhui Nie, Li Zhang, Hao Song, Yimeng An, Ziteng Liang, Jing Yang, Ruxia Ding, Shuo Liu, Qianqian Li, Tao Li, Zhimin Cui, Mengyi Zhang, Peng He, Youchun Wang, Xiaowang Qu, Zhongyu Hu, Qihui Wang, Weijin Huang   +18 more
doaj   +1 more source